Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia

• Published in: Blood 2007-03, Vol.109 (5), p.2256-2262
• Main Authors: Wagner, John E., Eapen, Mary, MacMillan, Margaret L., Harris, Richard E., Pasquini, Ricardo, Boulad, Farid, Zhang, Mei-Jie, Auerbach, Arleen D.
• Format: Article
• Language: English
• Subjects: Acute Disease; Adolescent; Adult; Biological and medical sciences; Blood Platelets - cytology; Bone Marrow Transplantation - adverse effects; Bone Marrow Transplantation - immunology; Cell Proliferation; Child; Child, Preschool; Chronic Disease; Fanconi Anemia - immunology; Fanconi Anemia - mortality; Fanconi Anemia - pathology; Fanconi Anemia - surgery; Female; Graft vs Host Disease - immunology; Graft vs Host Disease - pathology; Hematologic and hematopoietic diseases; Humans; Infant; Male; Medical sciences; Neutrophils - cytology; Probability; Prognosis; Survival Rate; Tissue Donors; Transplantation
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2006-07-036657

Bone marrow transplantation (BMT) is the only known cure for the hematologic manifestations of Fanconi anemia (FA). Potential benefits of unrelated donor BMT for FA, however, have been severely limited by graft rejection and treatment-related mortality with resultant poor survival. Therefore, we evaluated the impact of potential prognostic factors on hematopoietic recovery, graft-versus-host disease (GVHD), and mortality in 98 recipients of unrelated donor BMT who received transplants between 1990 and 2003. Probabilities of neutrophil (89% vs 69%; P = .02) and platelet (74% vs 23%; P < .001) recovery were higher after fludarabine-containing regimens than nonfludarabine-containing regimens. Risks of acute GVHD (relative risk [RR], 4.29; P < .001) were higher with non–T-cell–depleted grafts. The day-100 mortality rate was significantly higher after nonfludarabine-containing regimens than fludarabine-containing regimens (65% vs 24%, respectively; P < .001). Corresponding 3-year adjusted overall survival rates were 13% versus 52% (P < .001). In addition, mortality was higher in recipients who were older (> 10 years), who were cytomegalovirus (CMV) seropositive, and who received more than 20 blood product transfusions before BMT. Based on these results, significant practice changes are suggested: use of a fludarabine-containing conditioning regimen in the context of T-cell–depleted marrow allografts, and earlier referral for transplantation prior to excessive transfusions in patients with marrow failure.